相关实验视频
Updated: May 16, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.4K
应用人类遗传学来优先考虑凝血级联蛋白标,以预防缺血性中风
Iyas Daghlas1, Ville Karhunen2, Anthony S Kim1
1Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco (I.D., A.S.K.).
Stroke
|April 6, 2025
概括
遗传分析显示,有五种凝血蛋白与缺血性中风风险有因果关系,特别是心血管栓塞亚型. 这些发现区分了中风和静脉血栓栓塞 (VTE) 蛋白质关联,有助于向抗凝剂的开发.
科学领域:
- 遗传学 是一个遗传学.
- 心血管科学 心血管科学
- 血液学 血液学 血液学
背景情况:
- 凝血级联蛋白的个体间变异是已知的静脉血栓栓塞 (VTE) 的风险因素.
- 凝血因子和动脉缺血性中风风险之间的关联不太清楚.
- 这项研究调查了特定的凝血蛋白和缺血性中风之间的因果关系.
研究的目的:
- 为了确定凝血级联蛋白质的遗传代理.
- 确定这些遗传代理与缺血性中风风险和亚型的关联.
- 区分凝血蛋白在缺血性中风中的作用与VTE.
主要方法:
- 利用全基因组关联研究 (GWAS) 确定蛋白质水平和VTE风险的遗传代理.
- 采用了两个样本的孟德尔随机化和局部化分析.
- 检查了与缺血性中风 (62,100例) 和其亚型以及VTE (81,190例) 的关联.
主要成果:
- 确定了30个凝血因子的遗传代理,证实了已知的生物学.
- 发现了五种蛋白质与缺血性中风风险之间的因果关联:XI因子,高分子量激素原,蛋白质,可溶性PROCR (蛋白质C受体) 和γ'纤维素原.
- 这五种蛋白质与心血管栓塞性中风特别相关; γ'纤维素和前热血素也与大动脉动脉硬化性中风有关. 选择性地与VTE相关的其他几个因素.
结论:
- 特定的凝血级联组件涉及到缺血性中风的病原性.
- 与VTE相比,在缺血性中风中具有明显作用的已确定蛋白质.
- 这些发现可以指导新型抗凝血剂的开发,并优化它们在中风患者中的使用.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
570
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
570
Clot Retraction and Fibrinolysis
3.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.0K
Coagulation
3.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
3.8K
Extrinsic and Intrinsic Pathways of Hemostasis
4.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.2K
Disorders of Hemostasis
664
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
664
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
420
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
420

